Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA topoisomerase 2-beta (TOP2B) is a type IIA topoisomerase that regulates DNA topology by generating transient double-strand breaks, passing an intact DNA duplex through the break, and resealing the cleaved strands in an ATP-dependent manner. The N-terminal ATPase domain of TOP2B binds and hydrolyzes ATP, driving the conformational changes (such as clamp closure and dimerization) necessary for the catalytic cycle. Unlike its isoform TOP2A, which is primarily expressed in proliferating cells, TOP2B is constitutively expressed in both dividing and post-mitotic cells, including cardiomyocytes and neurons, where it plays a critical role in transcription and genomic stability.
In oncology, TOP2B is a major off-target of anthracycline chemotherapeutics (like doxorubicin), where drug-induced poisoning of TOP2B in cardiomyocytes leads to DNA double-strand breaks, mitochondrial dysfunction, and severe cardiotoxicity. Conversely, targeting the ATPase domain of TOP2B with catalytic inhibitors, such as dexrazoxane or the isoform-selective inhibitor topobexin, prevents ATP hydrolysis and locks the enzyme in a closed-clamp conformation. This prevents the formation of toxic cleavage complexes, offering a powerful strategy for cardioprotection during cancer chemotherapy.
Catalytic inhibition of topoisomerase II beta by binding to the ATPase domain, which prevents ATP hydrolysis and locks the enzyme in a closed-clamp conformation on DNA, thereby preventing DNA cleavage and protecting against anthracycline-induced cardiotoxicity. Alternatively, topoisomerase II poisons (such as anthracyclines and etoposide) stabilize the covalent cleavage complex, preventing DNA religation and leading to double-strand breaks.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA topoisomerase 2-beta (TOP2B).